Pfizer starting test of COVID-19 vaccine in children under 12
Pfizer and BioNTech announced on Tuesday that they will begin to test the effectiveness of their coronavirus vaccine in children younger than 12.
According to Reuters, the companies will conduct a study among nearly 4,500 children across more than 90 clinical sites located in the United States, Poland, Spain and Finland. The study will also follow a specific dosing regimen for certain age groups.
The companies plan to give children between the ages of 5 and 11 a dose of 10 micrograms and children and infants ages 6 months to 5 years a dose of 3 micrograms, the news outlet reported.
In March, Pfizer and BioNTech found their COVID-19 vaccine to be 100 percent effective in children ages 12 to 15. In a clinical trial of 2,260 adolescents, the vaccine was found to generate robust antibody responses.